Connect with us

Published

on

Jaap Arriens | Nurphoto | Getty Images

Microsoft’s multibillion-dollar investment in artificial intelligence firm OpenAI could face a full-blown merger investigation in the European Union, EU officials signaled Tuesday.

The European Commission, which is the executive arm of the EU, said that it was embarking on a competition investigation looking at the markets for virtual worlds and generative artificial intelligence.

As part of its assessment, the Commission said that it wants to understand how competitive these markets are currently and gain insight on how competition law can help these fields.

The EU Commission also said it is “looking into some of the agreements that have been concluded between large digital market players and generative AI developers and providers” and singled out the Microsoft-OpenAI tie-up as a particular deal it will be studying.

“The European Commission is checking whether Microsoft’s investment in OpenAI might be reviewable under the EU Merger Regulation,” the Commission said in a statement on Tuesday.

Microsoft did not immediately respond to a CNBC request for comment.

The Commission said it has sent requests for information to “several large digital players” and is also seeking views from interested parties, which have until March 11 to submit responses.

“Virtual worlds and generative AI are rapidly developing,” Vestager said in a statement Tuesday. “It is fundamental that these new markets stay competitive, and that nothing stands in the way of businesses growing and providing the best and most innovative products to consumers.”

Microsoft has put billions of dollars into OpenAI, the firm behind the popular AI chatbot ChatGPT. The company has integrated some OpenAI technology into its Office, Bing, and Windows products and provides OpenAI with its own Azure cloud computing tools.

The Redmond, Washington-based technology giant first invested in OpenAI in 2019, contributing $1 billion in cash.

The FTC and the UK's CMA are examining Microsoft's investment in OpenAI

The company then grabbed headlines last year, when it reportedly poured a further $10 billion into OpenAI, with its total investment to date reportedly swelling to $13 billion.

News of the EU review comes after the U.K.’s Competition and Markets Authority announced in December that it was launching an initial review into Microsoft’s investment. The U.S. Federal Trade Commission is also reportedly assessing the tie-up, according to Bloomberg News.

The CMA said it is assessing whether Microsoft’s stake in AI created a “relevant merger situation,” citing “a number of developments in the governance of OpenAI, some of which involved Microsoft” as a primary source of concern.

Earlier in the year, OpenAI faced a period of tumult when its CEO Sam Altman was ousted from the board in a shock move. In a dramatic turn of events, ex-Twitch CEO Emmett Shear briefly took the top job, before being removed and replaced with Altman, while the board was given a makeover.

As part of that refresh, Microsoft added its own observer to sit on the board, leading to concerns that the company may be exerting control over OpenAI. For its part, Microsoft has sought to stressed that its designated board observer, who was recently named Dee Templeton, is a nonvoting member.

At the time of the CMA announcement, Microsoft said that it did not in any way hold equity ownership in OpenAI, while OpenAI said that it remained independent and operates competitively.

“Their non-voting board observer does not provide them with governing authority or control over OpenAI’s operations,” an OpenAI spokesperson told CNBC via email in December.

“While details of our agreement remain confidential, it is important to note that Microsoft does not own any portion of OpenAI and is simply entitled to share of profit distributions,” Frank Shaw, Microsoft Chief Communications Officer, said in a December statement.

At the heart of concerns is Microsoft’s close partnership and investment in OpenAI, which gives the Redmond titan access to one of the most advanced developers of AI tools today. OpenAI’s GPT-4 large language model can handle a rumored 25,000 words of input text — a big step up from the existing ChatGPT limit of 4,096 characters.

Academics have said that GPT-4 has demonstrated human-level performance in various academic exams, while some AI researchers and technologists have speculated GPT-4 may come close to artificial general intelligence, or AGI, which is meant to be as smart or smarter than humans.

– CNBC’s Hayden Field and Kif Leswing contributed to this report

Continue Reading

Technology

Bitcoin accelerates its slide, falling toward $90,000 to start the week

Published

on

By

Bitcoin accelerates its slide, falling toward ,000 to start the week

Dado Ruvic | Reuters

Bitcoin briefly dropped below the $90,000 mark on Monday, extending its slide as investors continue to dump growth oriented assets like crypto and tech stocks.

The price of the flagship cryptocurrency was last lower by 3% at $91,358.66 to start the week, according to Coin Metrics. Earlier, it fell as low as $89,259.00. Bitcoin is down 10% in the past week.

Stock Chart IconStock chart icon

hide content

Bitcoin extends its slide as growth-oriented assets continue to get hit

Ether lost 7% Monday and the broader crypto market, as measured by the CoinDesk 20 index, dropped more than 5%. Shares of Coinbase and MicroStrategy slid 4% and 3%, respectively. Mara Holdings declined 4% and Core Scientific retreated by 2%.

Crypto assets’ decline began last week after stronger-than-expected payroll numbers caused a spike in bond yields and amid concerns about President-elect Donald Trump’s tariff plans – both of which gave a boost to the dollar while pressuring bitcoin and other risk assets.

“The need for liquidity is caused by FX spikes because of strong end-of-year U.S. economy number, the stock market rallying strong, and there are other places money is needed in the short-term,” said James Davies, co-founder and CEO at crypto trading platform Crypto Valley Exchange. “If we want bitcoin to act like a currency, we need to accept when it does, and this is one of those times. The U.S. Dollar has gotten stronger ad everything else including bitcoin is weaker when measured in dollars.”

Investor sentiment was optimistic coming into 2025, with markets looking forward to having a pro-crypto Congress and White House. That hope had outweighed any concern about macroeconomic-related speedbumps, until last week.

Investors are now warning that the first quarter of this year could be more turbulent for crypto than previously anticipated.

Bitcoin’s price grew 120% in 2024 but is down 3% so far in the new year.

Don’t miss these cryptocurrency insights from CNBC Pro:

Continue Reading

Technology

New AI tool for fighting health insurance denials could save hospitals billions, and help patients

Published

on

By

New AI tool for fighting health insurance denials could save hospitals billions, and help patients

The Waystar team celebrates its IPO at the Nasdaq

2024 Nasdaq, Inc. / Vanja Savic

Health-care payments company Waystar on Monday announced a new generative artificial intelligence tool that can help hospitals quickly tackle one of their most costly and tedious responsibilities: fighting insurance denials. 

Hospitals and health systems spend nearly $20 billion a year trying to overturn denied claims, according to a March report from the group purchasing organization Premier. 

“We think if we can develop software that makes people’s lives better in an otherwise stressful moment of time when they’re getting health-care, then we’re doing something good,” Waystar CEO Matt Hawkins told CNBC.

Waystar’s new solution, called AltitudeCreate, uses generative AI to automatically draft appeal letters. The company said the feature could help providers drive down costs and spare them the headache of digging through complex contracts and records to put the letters together manually. 

Hawkins led Waystar through its initial public offering in June, where it raised around $1 billion. The company handled more than $1.2 trillion in gross claims volume in 2023, touching about 50% of patients in the U.S. 

Claim denials have become a hot-button issue across the nation following the deadly shooting of UnitedHealthcare CEO Brian Thompson in December. Americans flooded social media with posts about their frustrations and resentment toward the insurance industry, often sharing stories about their own negative experiences. 

Read more CNBC reporting on AI

When a patient receives medical care in the U.S., it kicks off a notoriously complex billing process. Providers like hospitals, health systems or ambulatory care facilities submit an invoice called a claim to an insurance company, and the insurer will approve or deny the claim based on whether or not it meets the company’s criteria for reimbursement. 

If a claim is denied, patients are often responsible for covering the cost out-of-pocket. More than 450 million claims are denied each year, and denial rates are rising, Waystar said. 

Providers can ask insurers to reevaluate claim denials by submitting an appeal letter, but drafting these letters is a time-consuming and expensive process that doesn’t guarantee a different outcome.

Hawkins said that while there’s been a lot of discussion around claims denials recently, AltitudeCreate has been in the works at Waystar for the last six to eight months. The company announced an AI-focused partnership with Google Cloud in May, and automating claims denials was one of the 12 use cases the companies planned to explore.

Waystar has also had a denial and appeal management software module available for several years, Hawkins added.

AltitudeCreate is one tool available within a broader suite of Waystar’s AI offerings called AltitudeAI, which the company also unveiled on Monday. AltitudeCreate rolled out to organizations that are already using Waystar’s denial and appeal management software modules earlier this month at no additional cost, the company said. 

Waystar plans to make the feature more broadly available in the future. 

“In the face of all of this administrative waste in health-care where provider organizations are understaffed and don’t have time to even follow up on a claim when it does get denied, we’re bringing software to bear that helps to automate that experience,” Hawkins said.

Continue Reading

Technology

AWS and General Catalyst partner to speed up development of health-care AI tools

Published

on

By

AWS and General Catalyst partner to speed up development of health-care AI tools

Attendees walk through an expo hall at AWS re:Invent, a conference hosted by Amazon Web Services, at the Venetian in Las Vegas on Nov. 28, 2023.

Noah Berger | Getty Images Entertainment | Getty Images

Amazon Web Services and venture capital firm General Catalyst on Monday announced a new multi-year partnership in their latest push to carve out a piece of health-care’s growing artificial intelligence market. 

Through the collaboration, General Catalyst portfolio companies will use AWS’ services to build and roll out AI tools for health systems more quickly. Aidoc, which applies AI to medical imaging, and Commure, which automates provider workflows with AI, will be the first two companies to participate.

No financial terms were disclosed in the announcement.

“Without a strong partner like Amazon and AWS to stand alongside them, to co-develop and support these companies … it’s not going to move as fast as we hope,” Chris Bischoff, head of global health-care investing at General Catalyst, told CNBC in an interview. 

Health systems are strained in the U.S., with staff burnout, growing labor shortages and razor-thin margins. These challenges often seem enticing for enterprising tech startups to tackle, especially as the multi-trillion dollar health-care industry dangles the prospect of large financial returns. 

Hospitals operate in a complex, technology-weary and highly-regulated sector that can be difficult for startups to break into. General Catalyst is hoping to help its companies fast-track the development and go-to-market process by leveraging resources like computing power from AWS.  

Read more CNBC reporting on AI

General Catalyst is no stranger to taking big swings in health-care. 

The firm has closed more than 60 digital health deals since 2020, behind only Gaingels and Alumni Ventures, according to a December report from PitchBook. Last January, General Catalyst shocked the industry by announcing that its new business, the Health Assurance Transformation Company, planned to acquire an Ohio-based health system – an unprecedented move in venture capital. 

General Catalyst’s “deep understanding” of health systems’ financial and operating realities made it an attractive partner for AWS, Dan Sheeran, AWS’ general manager of Healthcare & Life Science, told CNBC. Sheeran and Bischoff began outlining the collaboration between the two groups after meeting in London around nine months ago.   

AWS also has an established presence in the health-care sector. The company offers more health- and life-sciences-specific services than any other cloud provider, according to a release, and it inked other high-profile AI partnerships with GE HealthCare, Philips and others last year. 

The partnership between General Catalyst and AWS will stretch over several years, but new tools from Aidoc and Commure are coming in 2025. Aidoc is exploring how it can use the cloud to tap data modalities across pathology, cardiology, genomics and other molecular information, for instance. 

Aidoc and Commure were selected to kick off the collaboration because they have both established a product-market fit, are operational and are focused on issues that are a high priority for AWS customers.

“GC has spent a lot of time thinking about how health systems can transform themselves, and we recognize that it’s not going to be through 1,000 companies, and we need solutions that are really enterprise grade,” Bischoff said. “Amazon shares the same vision, so we are starting with these two.”  

Though the partnership between General Catalyst and AWS is still in its early days, the organizations said they believe it will help serve as a way to meet the market’s growing demand for new solutions. 

“Health system leaders who want to realize the benefits of AI now have an easier way to accomplish that,” Sheeran said.

Continue Reading

Trending